Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tedizolid - Merck & Co

Drug Profile

Tedizolid - Merck & Co

Alternative Names: BAY 1192631; DA-70157; DA-70218; DA-7157; DA-7218; MK-1986; SIVEXTRO; Sivextro; Tedizolid phosphate; Torezolid; Torezolid phosphate; TR-700; TR-701; TR-701 FA; TR-701 free acid

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST; Merck & Co
  • Class Anti-infectives; Antibacterials; Fluorinated hydrocarbons; Oxazolidinones; Phosphates; Pyridines; Small molecules; Sodium compounds; Tetrazoles
  • Mechanism of Action Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase III Nosocomial pneumonia; Ventilator associated pneumonia
  • No development reported Bacteraemia; Gram-positive infections

Most Recent Events

  • 06 Jul 2023 Merck & Co completes a phase-III trial in Skin and soft tissue infections (In children, In infants) in US, Georgia, Guatemala, Latvia, Lithuania, Russia, Ukraine, Turkey, South Africa, Poland, Mexico, Germany, Bulgaria and Brazil (IV) (NCT03176134)
  • 26 Aug 2022 No development reported - Phase-I for Ventilator-associated-pneumonia in USA (PO)
  • 05 May 2022 Nabriva extends agreement with Merck to promote and distribute tedizolid in USA till December 2026
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top